Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
Control Crohn Safe Trial
- Conditions
- Interventions
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 158
- Registration Number
- NCT03917303
- Locations
- 🇳🇱
Maastricht University Medical Centre+, Maastricht, Netherlands
🇳🇱Zuyderland Medical Center, Sittard, Netherlands
🇳🇱VieCuri, Venlo, Netherlands
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 852
- Registration Number
- NCT03895203
- Locations
- 🇩🇪
Pa0010 40026, Ratingen, Germany
🇭🇺Pa0010 40030, Eger, Hungary
🇮🇹Pa0010 40084, Catania, Italy
Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-05-04
- Lead Sponsor
- Alvotech Swiss AG
- Target Recruit Count
- 390
- Registration Number
- NCT03849313
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, New South Wales, Australia
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
🇳🇿Christchurch Clinical Studies Trust Limited, Christchurch, Chistchurch, New Zealand
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT03823391
- Locations
- 🇺🇸
PCCR Solution /ID# 215457, Colleyville, Texas, United States
🇺🇸C.V. Mehta MD, Med Corporation /ID# 213068, Hemet, California, United States
🇺🇸Robin K. Dore MD, Inc /ID# 213045, Tustin, California, United States
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 315
- Registration Number
- NCT03739853
- Locations
- 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03737708
- Locations
- 🇰🇷
Site KR82003, Daegu, Korea, Republic of
🇰🇷Site KR82007, Daegu, Korea, Republic of
🇰🇷Site KR82002, Incheon, Korea, Republic of
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2274
- Registration Number
- NCT03662919
- Locations
- 🇫🇷
Research Site, Toulon, Provence-Alpes-Côte d'Azur, France
🇫🇷Research Site 2, La Rochelle, Nouvelle-Aquitaine, France
🇫🇷Research Site 3, Paris, Ile De France, France
Effects of Abatacept on Myocarditis in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 11
- Registration Number
- NCT03619876
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- University Hospital, Grenoble
- Target Recruit Count
- 50
- Registration Number
- NCT03561649
- Locations
- 🇫🇷
CHU de Saint-Etienne, Saint-Etienne, France
🇫🇷CH de Belfort, Belfort, France
🇫🇷CHU de Besançon, Besançon, France
Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Keio University
- Target Recruit Count
- 300
- Registration Number
- NCT03505008
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju, Korea, Republic of
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇯🇵Keio University Hospital, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.